Skip to Content
Merck

Acetate Promotes T Cell Effector Function during Glucose Restriction.

Cell reports (2019-05-16)
Jing Qiu, Matteo Villa, David E Sanin, Michael D Buck, David O'Sullivan, Reagan Ching, Mai Matsushita, Katarzyna M Grzes, Frances Winkler, Chih-Hao Chang, Jonathan D Curtis, Ryan L Kyle, Nikki Van Teijlingen Bakker, Mauro Corrado, Fabian Haessler, Francesca Alfei, Joy Edwards-Hicks, Leonard B Maggi, Dietmar Zehn, Takeshi Egawa, Bertram Bengsch, Ramon I Klein Geltink, Thomas Jenuwein, Edward J Pearce, Erika L Pearce
ABSTRACT

Competition for nutrients like glucose can metabolically restrict T cells and contribute to their hyporesponsiveness during cancer. Metabolic adaptation to the surrounding microenvironment is therefore key for maintaining appropriate cell function. For instance, cancer cells use acetate as a substrate alternative to glucose to fuel metabolism and growth. Here, we show that acetate rescues effector function in glucose-restricted CD8+ T cells. Mechanistically, acetate promotes histone acetylation and chromatin accessibility and enhances IFN-γ gene transcription and cytokine production in an acetyl-CoA synthetase (ACSS)-dependent manner. Ex vivo acetate treatment increases IFN-γ production by exhausted T cells, whereas reducing ACSS expression in T cells impairs IFN-γ production by tumor-infiltrating lymphocytes and tumor clearance. Thus, hyporesponsive T cells can be epigenetically remodeled and reactivated by acetate, suggesting that pathways regulating the use of substrates alternative to glucose could be therapeutically targeted to promote T cell function during cancer.